Novel Strategy for Three-Dimensional Fragment-Based Lead Discovery

被引:17
|
作者
Yuan, Haoliang [1 ]
Lu, Tao [1 ]
Ran, Ting [1 ]
Liu, Haichun [1 ]
Lu, Shuai [1 ]
Tai, Wenting [1 ]
Leng, Ying [1 ]
Zhang, Weiwei [1 ]
Wang, Jian [1 ]
Chen, Yadong [1 ]
机构
[1] China Pharmaceut Univ, Lab Mol Design & Drug Discovery, Sch Basic Sci, Nanjing 210009, Peoples R China
基金
中国国家自然科学基金;
关键词
DEPENDENT KINASE INHIBITORS; STRUCTURE-GUIDED DESIGN; HIGH-AFFINITY LIGANDS; C-MET INHIBITORS; DRUG DESIGN; CDK2; INHIBITORS; ANILINO PYRIMIDINES; SELECTIVE CLASS; BINDING MODE; POTENT;
D O I
10.1021/ci200003c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based drug design (FBDD) is considered a promising approach in lead discovery. However, for a practical application of this approach, problems remain to be solved. Hence, a novel practical strategy for three-dimensional lead discovery is presented in this work Diverse fragments with spatial positions and orientations retained in separately adjacent regions were generated by deconstructing well-aligned known inhibitors in the same target active site. These three-dimensional fragments retained their original binding modes in the process of new molecule construction by fragment linking and merging. Root-mean-square deviation (rmsd) values were used to evaluate the conformational changes of the component fragments in the final compounds and to identify the potential leads as the main criteria. Furthermore, the successful validation of our strategy is presented on the basis of two relevant tumor targets (CDK2 and c-Met), demonstrating the potential of our strategy to facilitate lead discovery against some drug targets.
引用
收藏
页码:959 / 974
页数:16
相关论文
共 50 条
  • [31] Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery
    M. Catherine Johnson
    Qiyue Hu
    Laura Lingardo
    Rose Ann Ferre
    Samantha Greasley
    Jiangli Yan
    John Kath
    Ping Chen
    Jacques Ermolieff
    Gordon Alton
    Journal of Computer-Aided Molecular Design, 2011, 25 : 689 - 698
  • [32] Fragment-based drug discovery
    Wendy A. Warr
    Journal of Computer-Aided Molecular Design, 2009, 23 : 453 - 458
  • [33] Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery
    Johnson, M. Catherine
    Hu, Qiyue
    Lingardo, Laura
    Ferre, Rose Ann
    Greasley, Samantha
    Yan, Jiangli
    Kath, John
    Chen, Ping
    Ermolieff, Jacques
    Alton, Gordon
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2011, 25 (07) : 689 - 698
  • [34] fragment-based ligand discovery
    Fischer, Marcus
    Hubbard, Roderick E.
    MOLECULAR INTERVENTIONS, 2009, 9 (01) : 22 - 30
  • [35] Fragment-based drug discovery
    Warr, Wendy A.
    JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2009, 23 (08) : 453 - 458
  • [36] Fragment-Based Drug Discovery
    Norton, Raymond S.
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2013, 66 (12) : 1463 - 1464
  • [37] Fragment-based discovery in spotlight
    Lipp, Elizabeth
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2007, 27 (19): : 22 - +
  • [38] Fragment-based lead design
    Tarasova, Olga A.
    Poroikov, V. V.
    RUSSIAN CHEMICAL REVIEWS, 2012, 81 (02) : 158 - 174
  • [39] Fragment-Based Lead Discovery: Screening and Optimizing Fragments for Thermolysin Inhibition
    Englert, Lisa
    Silber, Katrin
    Steuber, Holger
    Brass, Sascha
    Over, Bjoern
    Gerber, Hans-Dieter
    Heine, Andreas
    Diederich, Wibke E.
    Klebe, Gerhard
    CHEMMEDCHEM, 2010, 5 (06) : 930 - 940
  • [40] Hit and Lead Discovery with Explorative RL and Fragment-based Molecule Generation
    Yang, Soojung
    Hwang, Doyeong
    Lee, Seul
    Ryu, Seongok
    Hwang, Sung Ju
    ADVANCES IN NEURAL INFORMATION PROCESSING SYSTEMS 34 (NEURIPS 2021), 2021, 34